Conference

American College of Toxicology (ACT) 2021 Virtual Annual Meeting

Date

Sunday, November 14, 2021 - Wednesday, November 17, 2021

Location

Virtual
Charles River experts support biotechnology, pharmaceutical, medical device, and chemical companies throughout their product and drug development journey offering end-to-end solutions which encompasses discovery, toxicology, specialty toxicology, manufacturing, and various products.

Commitment to Innovation through Challenging Times

No matter the circumstances, our experts are excited to engage with our scientific communities and share insights about cell and gene therapy, vaccine, small molecule, biologics, and medical device development. We never stopped supporting biotechnology, pharmaceutical, medical device, and chemical companies throughout the pandemic, and we will continue ensuring that patients around the world have the safe and necessary products to better their health.

Our scientific presentations and posters will be available on-demand so that you don’t miss out on the opportunity to engage and exchange scientific insights during the ACT 2021 Annual Meeting. See our ACT scientific schedule below.

Our experts are ready to connect with you through the ACT 2021 Annual Meeting. With this meeting taking place virtually, we are ready to engage with you in your way and in your own time. We want to talk about your drug development goals and milestones, share insights, and ensure your success in the drug and product development stages.

Schedule a meeting with an expert at any time to get your questions answered or begin outlining a development program.

Monday, November 8, 2021, 12:00 p.m. - 1:00 p.m. EDT
ASO Development on Your Brain: Think about Your Intrathecal ASO Programs Start to Finish

Julie Douville

Sunday, November 14, 8:00 a.m – 11:30 a.m. EDT
CE1: Microbiome and Drug Development

Rana Samadfam and Alan Hoberman

Sunday, November 14, 8:00 a.m. – 11:30 a.m. EDT
CE02: Designing Nonclinical Study Programs for Ocular Therapeutics and Drugs with Off-Target Ocular Effects

Mark Vezina and Pramila Singh

Monday, November 15, 9:00 a.m. – 12:00 p.m. EDT
2. Symposium – Emerging Issues with Sprague Dawley or Wistar Rats in Nonclinical Studies

Steven Bulera

Tuesday, November 16, 9:00 a.m.– 12:00 p.m. EDT
7. Symposium—Preclinical Development of Gene Therapies Using AAV Vectors: Appraisal of State of the Art

Simon Authier and Shawna Jackman

Wednesday, November 17, 9:00 a.m. – 10:15 a.m. EDT
15. Mini-Symposium – This is Spinal Tap (Devices) Medical Device Biocompatibility Testing

Lyn Wancket

In Vitro Evaluation of Compound-related Changes on Rabbit Hemostasis by Thrombin Generation Assay
Anthony Pinçon, Sebastien Woaye Koi, Francoise Poitout-Belissent

A Six-Month Pre-clinical Safety and Biodistribution Study of Cyno-AT845, a Muscle-Directed AAV-based Gene Replacement Therapy for Pompe Disease
Neil Fitch
Co-authored with Audentes Therapeutics and Toxicologic Pathology Consulting

Intracerebroventricular Injection in the hTau.P301S Mouse: Development of a Mouse Model for the Evaluation of Potential Drug Candidates for Neurodegenerative Disorders
Gael Quesseveur, Sabine Nesme, Phillippe Vignand, Pascal Sibilia, Linda Allais

Recording and Analysis of Physiological Signals in Adult Male Rats using a Bluetooth-Based, Non Invasive External Telemetry System (DECRO® Jacket)
Jonathan Vial, Stephane Baudet, Christophe Bory, Marine Ravaz, VIrginie Roger
Co-authored with Etisense SAS

Evaluation of the NCG Mouse for Cell Therapy Toxicology Assessments
Viktorija Smutova, Camilla Para, Jenny Rowe, Steve Festin, Michelle Stoute, Christian Li, Simon Authier

Real-time MRI for Intraparenchymal Convection-enhanced Delivery (CED) Infusion in Large Animals with Target Coverage Quantification Using 7T MRI Masks
Jerneja Stare, Michael Accardi, Erik Larson, Said Maghezzi, Karen Wong, Christian Li, Simon Authier
Co-authored with ToXcel